Merck & Company, Inc. (MRK) Price Target Lowered to $67.00 at UBS AG

Merck & Company, Inc. (NYSE:MRK) had its target price cut by UBS AG from $72.00 to $67.00 in a research note released on Monday morning. They currently have a buy rating on the stock.

A number of other analysts have also recently commented on MRK. BMO Capital Markets reiterated a sell rating on shares of Merck & in a research report on Wednesday, July 5th. Citigroup Inc. set a $65.00 price objective on Merck & and gave the stock a hold rating in a research report on Wednesday, July 5th. BidaskClub cut Merck & from a hold rating to a sell rating in a research report on Tuesday, July 11th. Deutsche Bank AG reiterated a hold rating and set a $66.00 price objective (up previously from $64.00) on shares of Merck & in a research report on Monday, July 17th. Finally, Goldman Sachs Group, Inc. (The) reiterated a neutral rating and set a $74.00 price objective (up previously from $70.00) on shares of Merck & in a research report on Thursday, July 27th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the company’s stock. The stock has an average rating of Hold and an average price target of $67.07.

Shares of Merck & (NYSE MRK) traded up 1.051% on Monday, hitting $55.285. 13,286,783 shares of the stock traded hands. The firm’s 50 day moving average is $63.99 and its 200-day moving average is $63.61. Merck & has a 12 month low of $54.41 and a 12 month high of $66.80. The company has a market cap of $150.78 billion, a PE ratio of 29.932 and a beta of 0.80.

Merck & (NYSE:MRK) last posted its quarterly earnings data on Friday, October 27th. The company reported $1.11 EPS for the quarter, topping analysts’ consensus estimates of $1.03 by $0.08. The firm had revenue of $10.33 billion during the quarter, compared to analysts’ expectations of $10.54 billion. Merck & had a return on equity of 26.82% and a net margin of 11.60%. The firm’s quarterly revenue was down 2.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.07 EPS. Equities analysts predict that Merck & will post $3.92 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Merck & Company, Inc. (MRK) Price Target Lowered to $67.00 at UBS AG” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.com-unik.info/2017/10/31/merck-company-inc-mrk-price-target-lowered-to-67-00-at-ubs-ag.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Csenge Advisory Group acquired a new position in shares of Merck & in the 3rd quarter valued at about $1,243,000. SignalPoint Asset Management LLC acquired a new position in shares of Merck & in the 3rd quarter valued at about $384,000. Everence Capital Management Inc. lifted its stake in shares of Merck & by 4.5% in the 3rd quarter. Everence Capital Management Inc. now owns 64,225 shares of the company’s stock valued at $4,112,000 after purchasing an additional 2,770 shares in the last quarter. Tocqueville Asset Management L.P. lifted its stake in shares of Merck & by 0.5% in the 3rd quarter. Tocqueville Asset Management L.P. now owns 1,034,096 shares of the company’s stock valued at $66,213,000 after purchasing an additional 4,840 shares in the last quarter. Finally, FineMark National Bank & Trust lifted its stake in shares of Merck & by 22.1% in the 3rd quarter. FineMark National Bank & Trust now owns 215,868 shares of the company’s stock valued at $13,822,000 after purchasing an additional 39,096 shares in the last quarter. 72.86% of the stock is currently owned by institutional investors and hedge funds.

Merck & Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Analyst Recommendations for Merck & (NYSE:MRK)

What are top analysts saying about Merck & Company Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Merck & Company Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit